Catalent Inc (CTLT) Given Average Recommendation of “Hold” by Brokerages

Catalent Inc (NYSE:CTLT) has been assigned an average rating of “Hold” from the thirteen ratings firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $44.29.

A number of brokerages have recently commented on CTLT. Needham & Company LLC began coverage on Catalent in a report on Tuesday, September 12th. They set a “hold” rating and a $42.00 price objective on the stock. Zacks Investment Research lowered Catalent from a “hold” rating to a “sell” rating in a report on Wednesday. BidaskClub downgraded Catalent from a “buy” rating to a “hold” rating in a research note on Friday, September 15th. Bank of America restated a “buy” rating and set a $40.00 target price (up previously from $38.00) on shares of Catalent in a research note on Tuesday, August 29th. Finally, Piper Jaffray Companies restated a “buy” rating and set a $45.00 target price on shares of Catalent in a research note on Tuesday, August 29th.

Shares of Catalent (NYSE:CTLT) traded down $0.01 during midday trading on Thursday, hitting $41.94. The stock had a trading volume of 775,800 shares, compared to its average volume of 918,273. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.49 and a current ratio of 2.91. The firm has a market cap of $5,573.46, a price-to-earnings ratio of 29.34, a price-to-earnings-growth ratio of 2.70 and a beta of 1.41. Catalent has a fifty-two week low of $25.51 and a fifty-two week high of $43.39.

Catalent (NYSE:CTLT) last issued its quarterly earnings data on Monday, November 6th. The company reported $0.21 EPS for the quarter, beating the Zacks’ consensus estimate of $0.20 by $0.01. The business had revenue of $543.90 million for the quarter, compared to analyst estimates of $490.75 million. Catalent had a return on equity of 23.97% and a net margin of 5.01%. The firm’s revenue for the quarter was up 23.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.16 EPS. analysts predict that Catalent will post 1.46 earnings per share for the current year.

In other Catalent news, insider John R. Chiminski sold 181,458 shares of the firm’s stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $39.62, for a total value of $7,189,365.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Uwe Roehrhoff acquired 7,500 shares of Catalent stock in a transaction on Tuesday, November 21st. The stock was purchased at an average price of $39.22 per share, with a total value of $294,150.00. The disclosure for this purchase can be found here. 1.70% of the stock is currently owned by company insiders.

Hedge funds have recently made changes to their positions in the business. BlackRock Inc. lifted its position in shares of Catalent by 15.2% during the 2nd quarter. BlackRock Inc. now owns 17,512,661 shares of the company’s stock worth $614,695,000 after buying an additional 2,316,849 shares during the period. Vanguard Group Inc. lifted its position in shares of Catalent by 3.8% during the 2nd quarter. Vanguard Group Inc. now owns 10,119,431 shares of the company’s stock worth $355,192,000 after buying an additional 369,526 shares during the period. Janus Henderson Group PLC bought a new position in shares of Catalent during the 2nd quarter worth approximately $239,629,000. JPMorgan Chase & Co. lifted its position in shares of Catalent by 4.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 5,139,690 shares of the company’s stock worth $180,403,000 after buying an additional 226,705 shares during the period. Finally, State Street Corp lifted its position in shares of Catalent by 10.7% during the 2nd quarter. State Street Corp now owns 4,315,841 shares of the company’s stock worth $151,488,000 after buying an additional 418,196 shares during the period. Institutional investors own 99.37% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Catalent Inc (CTLT) Given Average Recommendation of “Hold” by Brokerages” was first published by Community Financial News and is owned by of Community Financial News. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at https://www.com-unik.info/2017/12/21/catalent-inc-ctlt-given-average-recommendation-of-hold-by-brokerages.html.

About Catalent

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.

Analyst Recommendations for Catalent (NYSE:CTLT)

What are top analysts saying about Catalent? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Catalent and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit